• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
2
Impact of person-centred care training and person-centred activities on quality of life, agitation, and antipsychotic use in people with dementia living in nursing homes: A cluster-randomised controlled trial.以人为主的照护训练和活动对养老院老年痴呆患者生活质量、激越和抗精神病药物使用的影响:一项整群随机对照试验。
PLoS Med. 2018 Feb 6;15(2):e1002500. doi: 10.1371/journal.pmed.1002500. eCollection 2018 Feb.
3
Dementia Care Mapping™ to reduce agitation in care home residents with dementia: the EPIC cluster RCT.痴呆症关爱映射™以减少养老院痴呆症患者的激越:EPIC 集群 RCT。
Health Technol Assess. 2020 Mar;24(16):1-172. doi: 10.3310/hta24160.
4
A group intervention to improve quality of life for people with advanced dementia living in care homes: the Namaste feasibility cluster RCT.一项改善养老院中晚期痴呆症患者生活质量的团体干预措施:Namaste 可行性聚类 RCT。
Health Technol Assess. 2020 Jan;24(6):1-140. doi: 10.3310/hta24060.
5
A systematic review of the clinical effectiveness and cost-effectiveness of sensory, psychological and behavioural interventions for managing agitation in older adults with dementia.对感官、心理和行为干预措施在管理老年痴呆症患者激越方面的临床有效性和成本效益的系统评价。
Health Technol Assess. 2014 Jun;18(39):1-226, v-vi. doi: 10.3310/hta18390.
6
A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer's disease and agitated behaviours: the HTA-SYMBAD trial.一项实用的、多中心的、双盲、安慰剂对照随机试验,旨在评估米氮平和卡马西平在阿尔茨海默病伴激越行为患者中的安全性、临床疗效和成本效益:HTA-SYMBAD 试验。
Health Technol Assess. 2023 Oct;27(23):1-108. doi: 10.3310/VPDT7105.
7
8
9
Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation.行为修正干预对初级保健中无法用医学解释的症状:系统评价和经济评估。
Health Technol Assess. 2020 Sep;24(46):1-490. doi: 10.3310/hta24460.
10

DOI:10.3310/pgfar08060
PMID:32721145
Abstract

BACKGROUND

The effective management of agitation and other neuropsychiatric and behavioural symptoms in people with dementia is a major challenge, particularly in care home settings, where dementia severity is higher and there is limited training and support for care staff. There is evidence for the value of staff training and the use of psychosocial approaches; however, no intervention currently exists that combines these elements into an intervention that is fit for purpose and effective in these settings based on evidence from a randomised controlled trial.

OBJECTIVE

The objective was to develop and evaluate a complex intervention to improve well-being, reduce antipsychotic use and improve quality of life in people with dementia in care homes through person-centred care, management of agitation and non-drug approaches.

DESIGN

This was a 5-year programme that consisted of six work packages. Work package 1 consisted of two systematic reviews of personalised psychosocial interventions for behavioural and psychological symptoms for people with dementia in care homes. Work package 2 consisted of a metasynthesis of studies examining implementation of psychosocial interventions, in addition to developing a draft Well-being and Health for people with Dementia (WHELD) programme. Work package 3 consisted of a factorial study of elements of the draft WHELD programme in 16 care homes. Work package 4 involved optimisation of the WHELD programme based on work package 3 data. Work package 5 involved a multicentre randomised controlled trial in 69 care homes, which evaluated the impact of the optimised WHELD programme on quality of life, agitation and overall neuropsychiatric symptoms in people with dementia. Work package 6 focused on dissemination of the programme.

SETTING

This programme was carried out in care homes in the UK.

PARTICIPANTS

Participants of this programme were people with dementia living in care homes, and the health and care professionals providing treatment and care in these settings.

RESULTS

Work package 1: reviews identified randomised controlled trials and qualitative evidence supporting the use of psychosocial approaches to manage behavioural symptoms, but highlighted a concerning lack of evidence-based training manuals in current use. Work package 2: the meta-analysis identified key issues in promoting the use of interventions in care homes. The WHELD programme was developed through adaptation of published approaches. Work package 3: the factorial trial showed that antipsychotic review alone significantly reduced antipsychotic use by 50% (odds ratio 0.17, 95% confidence interval 0.05 to 0.60). Antipsychotic review plus social interaction significantly reduced mortality (odds ratio 0.36, 95% confidence interval 0.23 to 0.57), but this group showed significantly worse outcomes in behavioural and psychological symptoms of dementia than the group receiving neither antipsychotic review nor social interaction (mean difference 7.37 symptoms, 95% confidence interval 1.53 to 13.22 symptoms). This detrimental impact was reduced when combined with social interaction (mean difference –0.44 points, 95% confidence interval –4.39 to 3.52 points), but with no significant benefits for agitation. The exercise intervention significantly improved neuropsychiatric symptoms (mean difference –3.58 symptoms, 95% confidence interval –7.08 to –0.09 symptoms) but not depression (mean difference –1.21 points, 95% confidence interval –4.35 to 1.93 points). Qualitative work with care staff provided additional insights into the acceptability and feasibility of the intervention. Work package 4: optimisation of the WHELD programme led to a final version that combined person-centred care training with social interaction and pleasant activities. The intervention was adapted for delivery through a ‘champion’ model. Work package 5: a large-scale, multicentre randomised controlled trial in 69 care homes showed significant benefit to quality of life, agitation and overall neuropsychiatric symptoms, at reduced overall cost compared with treatment as usual. The intervention conferred a statistically significant improvement in quality of life (Dementia Quality of Life Scale – Proxy -score of 2.82, mean difference 2.54, standard error of measurement 0.88, 95% confidence interval 0.81 to 4.28, Cohen’s effect size of 0.24;  = 0.0042). There were also statistically significant benefits in agitation (Cohen-Mansfield Agitation Inventory -score of 2.68, mean difference –4.27, standard error of measurement 1.59, 95% confidence interval –7.39 to –1.15, Cohen’s effect size of 0.23;  = 0.0076) and overall neuropsychiatric symptoms (Neuropsychiatric Inventory – Nursing Home version -score of 3.52, mean difference –4.55, standard error of measurement 1.28, 95% confidence interval –7.07 to –2.02, Cohen’s of 0.30;  < 0.001). The WHELD programme contributed to significantly lower health and social care costs than treatment as usual (cost difference –£4740, 95% confidence interval –£6129 to –£3156). Focus groups were conducted with 47 staff up to 12 months after the end of work package 5, which demonstrated sustained benefits. Work package 6: the outputs of the programme were translated into general practitioner workshops and a e-learning module, an updated national best practice guideline and a portfolio of lay and care home outreach activities.

LIMITATIONS

Residents with dementia were not involved in the qualitative work.

CONCLUSIONS

The WHELD programme is effective in improving quality of life and reducing both agitation and overall neuropsychiatric symptoms in people with dementia in care homes. It provides a structured training and support intervention for care staff, with lower overall costs for resident care than treatment as usual.

FUTURE WORK

It will be important to consider the long-term sustainability of the WHELD programme and cost-effective means of long-term implementation.

TRIAL REGISTRATION

Current Controlled Trials ISRCTN40313497 and ISRCTN62237498.

FUNDING

This project was funded by the National Institute for Health Research (NIHR) Programme Grants for Applied Research programme and will be published in full in ; Vol. 8, No. 6. See the NIHR Journals Library website for further project information.

摘要